DelRicht Research is proud to highlight the exceptional performance of our investigators and site teams in a US-based Phase 2 trial for diarrhea-predominant irritable bowel syndrome (IBS-D). Over an ambitious 19-month enrollment period, our network not only exceeded its assigned enrollment target but set the bar for performance across all participating sites.

Surpassing Enrollment Targets

The sponsor’s goal for this national study was to enroll 450 participants across 75 sites. DelRicht’s assigned goal was 48 participants across eight locations. By the close of enrollment, our sites had enrolled 172 participants, achieving 358% of the goal and outperforming many sites nationwide.

Dr. E. Marshall Newton (Charleston, SC) was recognized as the top enroller overall, while several other DelRicht sites ranked within the top five. In addition, Dr. Matthew Mintz (Rockville, MD) achieved First Patient First Visit (FPFV), underscoring the network’s ability to activate within 55 days from site selection and quickly engage participants from the start.

This result reflects more than just recruitment; it demonstrates our ability to operationalize a study with complex behavioral and reporting requirements while sustaining participant engagement.

Tackling Protocol Complexity with Precision

Two key challenges emerged during execution. First was maintaining the ≥70% diary compliance required for eligibility and continued participation, as falling below this threshold classified participants as non-responders. Second was ensuring thorough education on pain scale anchoring and the correct use of the Bristol Stool Scale for stool reporting, both critical to accurate data collection.

To address compliance, our data team implemented proactive tracking of diary completion and provided timely re-education to participants at risk of falling below the threshold. For stool reporting, the study team supplied excellent visual training tools, which our sites used to reinforce understanding and improve accuracy. This hands-on approach helped ensure participants remained engaged, informed, and compliant throughout the trial.

Community-Driven Engagement, Network-Level Impact

The success of this trial was built on strong investigator leadership and trusted relationships within each community. Our participating principal investigators leveraged their patient relationships and practice networks to identify, engage, and retain eligible participants, ensuring both high enrollment and strong data integrity:

Dr. Michael Lovelace | Louisville, KY
Dr. Amy Roberts | Town & Country, MO
Dr. Rachael Murphy | Mandeville, LA
Dr. E. Marshall Newton | Charleston, SC
Dr. Sean Kerby | Gulfport, MS
Dr. Patrick Dennis | New Orleans, LA
Dr. Matthew Mintz | Rockville, MD
Dr. Melissa Jones | Charlotte, NC

What This Means for Sponsors and CROs

This trial reinforces the value of:

– Proactive compliance monitoring to maintain participant eligibility
– Investigator-led education to ensure data accuracy
– Site networks with established community trust for rapid, sustained enrollment

Partner With Us

At DelRicht Research, we don’t just meet enrollment goals; we exceed them through a combination of operational precision, strong investigator performance, and community engagement. If you’re seeking a site network capable of delivering high-quality results in high-barrier trials, we’d love to connect.

Learn more about our work in gastroenterology and other therapeutic areas at www.DelRichtResearch.com or reach out to explore partnership opportunities.